Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Postoperative Radiation for Pathologic Stage T4 Colon Cancers Receiving Adjuvant Chemotherapy.

Margalit O, Mamtani R, Lawrence YR, Yang YX, Reiss KA, Golan T, Halpern N, Aderka D, Giantonio B, Shacham-Shmueli E, Boursi B.

Clin Colorectal Cancer. 2019 Apr 13. pii: S1533-0028(18)30520-6. doi: 10.1016/j.clcc.2019.04.004. [Epub ahead of print]

PMID:
31097386
2.

Locally advanced rectal adenocarcinoma: Are preoperative short and long course radiotherapy truly equivalent?

Margalit O, Mamtani R, Lawrence YR, Yang YX, Baruch EN, Reiss KA, Golan T, Halpern N, Aderka D, Giantonio B, Shacham-Shmueli E, Boursi B.

Mol Clin Oncol. 2019 May;10(5):555-559. doi: 10.3892/mco.2019.1825. Epub 2019 Mar 14.

3.

Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma.

Margalit O, Mamtani R, Kopetz S, Yang YX, Lawrence YR, Abu-Gazala S, Reiss KA, Golan T, Halpern N, Aderka D, Giantonio B, Shacham-Shmueli E, Boursi B.

Oncologist. 2019 Jan 29. pii: theoncologist.2018-0333. doi: 10.1634/theoncologist.2018-0333. [Epub ahead of print]

PMID:
30696723
4.

A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification-Defining novel predictive and prognostic markers in stage III colon cancer.

Margalit O, Mamtani R, Yang YX, Reiss KA, Golan T, Halpern N, Aderka D, Giantonio B, Shacham-Shmueli E, Boursi B.

Eur J Cancer. 2018 Jun;96:105-110. doi: 10.1016/j.ejca.2018.03.022. Epub 2018 Apr 24.

PMID:
29698932
5.

Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer.

Margalit O, Mamtani R, Yang YX, Reiss KA, Golan T, Halpern N, Aderka D, Giantonio B, Shacham-Shmueli E, Boursi B.

Eur J Cancer. 2018 May;94:1-5. doi: 10.1016/j.ejca.2018.01.112. Epub 2018 Mar 20.

PMID:
29502035
6.

Phenotypic characteristics of colorectal cancer in BRCA1/2 mutation carriers.

Grinshpun A, Halpern N, Granit RZ, Hubert A, Hamburger T, Laitman Y, Shacham-Shmueli E, Peerless Y, Friedman E, Peretz T.

Eur J Hum Genet. 2018 Mar;26(3):382-386. doi: 10.1038/s41431-017-0067-1. Epub 2018 Jan 10.

7.

Short- and Long-Term Survival in Metastatic Pancreatic Adenocarcinoma, 1993-2013.

Golan T, Sella T, Margalit O, Amit U, Halpern N, Aderka D, Shacham-Shmueli E, Urban D, Lawrence YR.

J Natl Compr Canc Netw. 2017 Aug;15(8):1022-1027. doi: 10.6004/jnccn.2017.0138.

PMID:
28784864
8.

Clinical course and outcome of patients with high-level microsatellite instability cancers in a real-life setting: a retrospective analysis.

Halpern N, Goldberg Y, Kadouri L, Duvdevani M, Hamburger T, Peretz T, Hubert A.

Onco Targets Ther. 2017 Mar 29;10:1889-1896. doi: 10.2147/OTT.S126905. eCollection 2017.

9.

Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer.

Halpern N, Sonnenblick A, Uziely B, Divinsky L, Goldberg Y, Hamburger T, Peretz T, Kadouri L.

Int J Cancer. 2017 May 1;140(9):2145-2149. doi: 10.1002/ijc.30616. Epub 2017 Feb 8.

10.

Mutated MCM9 is associated with predisposition to hereditary mixed polyposis and colorectal cancer in addition to primary ovarian failure.

Goldberg Y, Halpern N, Hubert A, Adler SN, Cohen S, Plesser-Duvdevani M, Pappo O, Shaag A, Meiner V.

Cancer Genet. 2015 Dec;208(12):621-4. doi: 10.1016/j.cancergen.2015.10.001. Epub 2015 Oct 22.

PMID:
26806154
11.

Lynch Syndrome in high risk Ashkenazi Jews in Israel.

Goldberg Y, Kedar I, Kariiv R, Halpern N, Plesser M, Hubert A, Kaduri L, Sagi M, Lerer I, Abeliovich D, Hamburger T, Nissan A, Goldshmidt H, Solar I, Geva R, Strul H, Rosner G, Baris H, Levi Z, Peretz T.

Fam Cancer. 2014 Mar;13(1):65-73. doi: 10.1007/s10689-013-9675-2.

PMID:
23990280
12.

The effect of integration of non-cognitive parameters on medical students' characteristics and their intended career choices.

Halpern N, Bentov-Gofrit D, Matot I, Abramowitz MZ.

Isr Med Assoc J. 2011 Aug;13(8):488-93.

Supplemental Content

Loading ...
Support Center